VK2735 Development Programs - VANQUISH Phase 3 program is underway for VK2735, a GLP-1/GIP dual agonist for obesity[7, 67] - VENTURE Oral Phase 2 obesity study for VK2735 Oral, a GLP-1/GIP dual agonist, successfully achieved its primary endpoint[7, 10] - An Amylin agonist for obesity has an IND planned for 1Q26[7, 8] - VK2809, a selective thyroid receptor-β agonist for MASH, reported successful Phase 2b data in 2Q24[7, 8] - VK0214, a selective thyroid receptor-β agonist for X-ALD, reported successful Phase 1b data in 4Q24[7, 8] VK2735 Oral Phase 1 Study Results - After 28 days of oral dosing, up to 8.2% reduction in body weight was observed[22] - At 100 mg dose, up to approximately 7% placebo-adjusted weight loss was observed[15] - Weight loss effects were largely maintained through Day 57, four weeks from the last study dose[20] VK2735 VENTURE Oral Phase 2a Study Results - Up to 12.2% reduction from baseline in body weight was observed after 13 weeks[29, 32, 48] - A statistically significant difference vs placebo was observed at all time points for doses >15 mg[34] - In an exploratory maintenance cohort, down-titration from 90mg to 30mg produced continued gradual weight loss through Week 13[42] VK2735 Subcutaneous Formulation VENTURE Phase 2 Study Results - Up to 14.7% mean weight loss was observed after 13 weeks of VK2735 treatment[55, 66] - In the MAD study, a dose-dependent improvement in weight loss of up to 7.8% (6% placebo-adjusted) was reported after 28 days in subjects with BMI ≥30[50] Financial Information - As of September 30, 2025, the company had $714.57 million in cash and short-term investments[74] - Cash burn year-to-date as of September 30, 2025, was $188.042 million[74]

Company Overview - Viking Therapeutics is a San Diego-based company focused on metabolic and endocrine disorders with approximately 55 employees [3]. Clinical Programs - The company is developing VK2735, a GLP-1/GIP dual agonist for obesity, which is currently in a Phase III program known as the VANQUISH program [3]. - An oral formulation of VK2735 has recently completed a Phase II study, with data to be discussed in the presentation [3]. - An amylin agonist is approaching the clinic, with an IND filing expected in the first quarter [4]. - Additional programs include VK2809, which has completed a Phase IIb study in MASH, and VK0214, which has gone through a Phase Ib study in X-linked adrenoleukodystrophy; however, these programs are not actively being developed [4].

Viking Therapeutics Conference Call Summary Company Overview - **Company**: Viking Therapeutics (NasdaqCM: VKTX) - **Focus**: Metabolic and endocrine disorders - **Location**: San Diego, California - **Employees**: Approximately 55 Key Programs and Developments - **VK2735**: A GLP-1 GIP dual agonist for obesity - Currently in Phase III program called the VANQUISH program [4][35] - Oral formulation recently completed Phase II study [4][35] - **Amylin Agonist**: Expected to file an IND in the first quarter of 2026 [5][36] - **VK2809**: A thyroid receptor beta agonist that has completed a Phase IIb study in NASH [5] - **VK0214**: Another thyroid receptor beta agonist that has completed a Phase Ib study in X-linked adrenoleukodystrophy [5] Clinical Data and Efficacy - **VK2735 Oral Formulation**: - Phase II study showed up to 12.2% body weight reduction after 13 weeks of dosing [20][29] - Weight loss maintained for four weeks after the last dose [10][20] - Excellent tolerability with most adverse events classified as mild to moderate [21][29] - **VK2735 SubQ Formulation**: - Phase II study showed weight loss of 9% to 15% from baseline after 13 weeks [25][30] - Durable weight loss observed 21 days after the last dose [23][30] - Excellent tolerability with 98% of adverse events classified as mild to moderate [24][30] Pipeline and Future Studies - **VANQUISH Phase III Studies**: - VANQUISH I: Completed enrollment, focusing on obesity [30][35] - VANQUISH II: Expected to complete enrollment in the first quarter of next year [30][35] - **Maintenance Study**: Ongoing with a focus on transitioning from weekly to monthly dosing [33][34] Financial Overview - **Cash Position**: Over $700 million as of the third quarter, expected to fund through the VANQUISH Phase III data readouts [34][35] Additional Insights - The company is prioritizing mid-range doses for the oral formulation based on pharmacokinetics and gastrointestinal tolerability [37] - The potential for transitioning from SubQ to oral dosing to maintain weight loss is being explored [37] This summary encapsulates the key points from the Viking Therapeutics conference call, highlighting the company's focus on metabolic disorders, clinical program advancements, and financial health.

Core Insights - Viking Therapeutics has completed patient enrollment ahead of schedule for its Phase 3 VANQUISH-1 clinical trial of VK2735, indicating strong interest in new obesity treatments [1][3] - The trial enrolled approximately 4,650 adults with obesity or overweight conditions, assessing the efficacy and safety of VK2735 over 78 weeks [2] - Positive results from the Phase 2 VENTURE study of VK2735 showed significant weight reduction and favorable safety profiles [4] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with VK2735 being a dual agonist of GLP-1 and GIP receptors [1][6] - The company is also developing VK2809 for lipid and metabolic disorders and VK0214 for X-linked adrenoleukodystrophy [7] Clinical Trials - The Phase 3 VANQUISH-1 study is a randomized, double-blind, placebo-controlled trial with four treatment arms, focusing on weight change from baseline as the primary endpoint [2] - A 52-week extension period is included for participants to continue treatment after the primary dosing period [2] - Concurrently, the Phase 3 VANQUISH-2 study is enrolling patients with type 2 diabetes and obesity, expected to complete enrollment in Q1 2026 [3] Mechanism of Action - VK2735 acts on GLP-1 and GIP receptors, which are known to decrease glucose levels, reduce appetite, and improve insulin sensitivity [5] - The dual agonist approach aims to enhance therapeutic benefits compared to existing treatments [5]

Market Overview - Major U.S. indices closed mixed, with the Dow Jones Industrial Average up 1.2% to 47,927.96 and the S&P 500 up 0.2% to 6,846.61, while the Nasdaq fell 0.25% to 23,468.30 [1] Advanced Micro Devices Inc. (AMD) - AMD shares closed down 2.65% at $237.52, with an intraday high of $248.46 and a low of $234.64; however, the stock rose nearly 4.8% to $248.87 in after-hours trading [1][2] - AMD set ambitious growth targets during its analyst day, anticipating a revenue compound annual growth rate exceeding 35% over the next three to five years, driven by its expanding portfolio in high-performance and AI compute [2] Oklo Inc. (OKLO) - Oklo's stock fell 6.50% to close at $104.22, with a high of $111 and a low of $103.64; it rose nearly 1.8% to $106.09 in extended trading [3][4] - The company reported a wider-than-expected loss for Q3, with a loss of $0.20 per share, missing analyst expectations of a 12-cent loss, primarily due to payroll and stock-based compensation expenses [3] - The Department of Energy approved the Nuclear Safety Design Agreement for Oklo's Aurora Fuel Fabrication Facility, which will supply fuel for its first commercial-scale reactor [4] AppLovin Corp. (APP) - AppLovin shares declined 8.66% to finish at $594.91, attributed to a broader market pause in the high-growth tech sector rather than company-specific news [5] Viking Therapeutics Inc. (VKTX) - Viking Therapeutics saw a 7.49% increase, closing at $40.60, with a high of $40.69 and a low of $37.06; it rose 4.1% to $42.28 in after-hours trading [6] - Stanley Druckenmiller's family office purchased about 549,000 shares at $25.33 in Q2, with renewed investor optimism around the company's weight-loss drug pipeline [7] Novo Nordisk A/S (NVO) - Novo Nordisk shares rose 6.99% to $49.15, with an intraday high of $49.42 and a low of $47.05; the stock rose 1.3% to $49.79 in after-hours trading [8] - Despite losing a bidding war for Metsera Inc. to Pfizer, Novo Nordisk's stock gained as the company cut the price of its Wegovy drug in India to capture market share in the obesity treatment market [8]

Core Insights - Viking Therapeutics has seen a recovery in stock price following the release of positive phase 2 clinical trial results for its lead drug candidate VK2735, an oral weight loss formulation [1][2] Company Overview - VK2735 is a GLP-1 and GIP agonist weight loss drug being tested in both subcutaneous and oral formulations, with the subcutaneous version currently in phase 3 trials for obesity and type 2 diabetes, expected to yield results in 2027 [2] - The company has a market capitalization of $4 billion, with a current stock price of $36.76, and a 52-week price range of $18.92 to $68.87 [3] Clinical Trial Insights - The oral formulation of VK2735 has shown excellent efficacy, safety, and tolerability in phase 1 trials, and phase 2 results also demonstrated efficacy [4] - Despite a 20% discontinuation rate in the oral VK2735 group during phase 2 trials, the placebo group had a 13% discontinuation rate, indicating potential challenges with the trial cohort [5] Future Prospects - Management has initiated a phase 1 trial to explore the use of VK2735 (oral) as a maintenance dose in combination with VK2735 (subcutaneous), with results expected in 2026, indicating ongoing development and potential commercialization of the oral formulation [6]

Core Insights - Stanley Druckenmiller's investment in Viking Therapeutics Inc (VKTX) has proven to be a timely and strategic move, with the stock rising nearly 36% since his entry [1][2][3] - The stock's recent performance is attributed to both technical indicators and positive sentiment surrounding its weight-loss drug pipeline, which is compared to larger competitors in the GLP-1 market [2][6] Investment Details - Druckenmiller's family office acquired approximately 549,000 shares at an average price of $25.33 during the second quarter, resulting in a current position valued at around $14.5 million as the stock trades at $34.63 [1][3] - The investment represents a modest 0.37% allocation in the portfolio, but has gained significant value as the stock rebounded from a slump earlier in 2024 [2][6] Technical Analysis - The stock has formed a Golden Cross pattern, with the 50-day moving average crossing above the 200-day moving average, indicating a potential new uptrend [3][4] - Momentum indicators such as MACD at 1.58 and RSI at 54.18 suggest a healthy strength in the stock, while short-term averages remain above long-term levels, confirming trend alignment [4][5] Market Context - Viking Therapeutics is positioned as a smaller player in the biotech sector, particularly in the weight-loss drug market, which is gaining attention and could lead to significant growth opportunities [2][6] - The timing of Druckenmiller's investment aligns with a broader trend of macro inflection points, showcasing his ability to identify promising opportunities in the market [5][6]

Group 1 - The article emphasizes the importance of not only identifying great stocks but also knowing the timing and strategy for buying and taking profits [1] - It introduces the Cash Management Discipline, focusing on utilizing cash as a strategic position for overall investment success [1] - The article highlights that while many trading and investing rules are well-known, they are reinforced as a disciplined approach [1] Group 2 - The company prides itself on stock picking, indicating that even well-known stocks require careful selection [1] - Paying subscribers receive curated lists for specific sectors, including Microcap Biotech, Aviation+Space, and Asset Light Stocks [1] - A two-week trial is offered to potential subscribers to experience the service [1]

Core Insights - Viking Therapeutics' stock experienced significant volatility, surging over 120% after positive phase 2 trial results for its weight loss candidate VK2735, but has since lost 47% over the past year, although it has gained 16% in the last three months [1][2][6] Company Overview - Viking Therapeutics is focused on developing VK2735, a weight loss candidate that is currently in phase 3 trials, with an oral version in phase 2 [2][3] - VK2735 is categorized alongside GLP-1 receptor agonists, which are currently leading the weight loss market, dominated by companies like Novo Nordisk and Eli Lilly [3][4] Market Potential - The weight loss drug market is projected to approach $100 billion by the end of the decade, indicating significant revenue potential for new entrants like Viking [6][4] - Viking's VK2735 demonstrated an average weight loss of up to 13.1% after 13 weeks in phase 2 trials, with no observed plateau, suggesting continued weight loss potential [4][6] Stock Performance - Despite a decline from its peak, the drop in Viking's stock price is not attributed to negative company news but rather to profit-taking by investors and unmet acquisition expectations [7] - The current market cap of Viking Therapeutics is approximately $4 billion, with a stock price range over the past year between $18.92 and $79.10 [6] Upcoming Catalysts - Viking is scheduled to present data on VK2735 at two medical conferences, which may reinforce the drug's significance and support optimism about its market potential [9][10][11] - The presentations will cover the impact of VK2735 on prediabetes and metabolic syndrome, as well as its design in phase 3 studies for obesity and type 2 diabetes patients [10][11][12] Investment Considerations - The current momentum in Viking's stock suggests it may be a favorable investment opportunity, although investors are advised to take a measured approach rather than rushing to buy before the upcoming presentations [12][13]

Core Insights - The weight loss and diabetes drug market is experiencing significant growth, driven by demand for effective treatments and new competitors entering the space [1][3] - Eli Lilly and Novo Nordisk remain the leading companies, with Eli Lilly gaining market share and accounting for nearly 60% of prescriptions in the injectable obesity and diabetes class [2][9] - The market is projected to reach approximately $100 billion by the end of the decade, with a potential 25 to 50 million U.S. patients using GLP-1s by 2030 [3][12] Market Dynamics - Eli Lilly has outperformed Novo Nordisk, increasing its market share from 53% in Q1 to 57% in Q2 of the current year, attributed to superior efficacy and safety of its drugs [9][10] - Novo Nordisk is facing challenges, including a nearly 40% drop in stock value this year and a need to cut its workforce by 11.5% to regain market footing [11][14] - The competition is intensifying, with many pharmaceutical companies investing in obesity drugs, often through partnerships with smaller developers [4][42] Access and Coverage Issues - Access to GLP-1s remains limited due to insurance coverage gaps, with many insurers not covering obesity treatments, leading to high out-of-pocket costs for patients [5][23] - Coverage for GLP-1s for obesity has slightly increased, with 36% of surveyed companies providing such coverage, up from 34% in 2024 [24] - Employers are hesitant to cover these high-cost drugs due to concerns about long-term patient adherence and potential weight regain [25][28] Future Developments - Both Eli Lilly and Novo Nordisk are working on oral formulations of GLP-1s, which could significantly change market dynamics and improve patient access [30][34] - Analysts predict that oral pills could capture around 24% of the weight loss drug market by 2030, with Eli Lilly expected to lead this segment [34][35] - The success of new oral treatments will depend on their pricing and effectiveness compared to existing injectable options [40][39] Competitive Landscape - The market is seeing a variety of new entrants and experimental drugs, with companies exploring different mechanisms for weight loss and less frequent dosing [41][42] - Novo Nordisk and Eli Lilly are also looking into new hormone-targeting treatments to expand their portfolios beyond current offerings [45][46] - The competitive landscape is evolving, with potential partnerships between smaller biotech firms and larger pharmaceutical companies to enhance drug development [51]